Effect of Dipyridamole Treatment on Proteinuria in Pediatric Renal Disease
- 1 January 1986
- journal article
- research article
- Published by S. Karger AG in Nephron
- Vol. 44 (3), 174-179
- https://doi.org/10.1159/000183981
Abstract
The effect of dipyridamole on proteinuria was studied in 60 children with various renal diseases. A significant decrease in 24-hour urine protein excretion was observed within a few months after treatment in 32 (53%) of the patients with minimal or moderate mesangial proliferation. The effect was reproducible and paralleled by a reduction in plasma levels of .beta.-thromboglobulin. Renal function in patients significantly improved with the therapeutical effect. The appropriate dosage was 4-10 mg/kg daily and no serious toxicity was seen despite large dosage and even in long-term application. The data suggest that dipyridamole treatment appears safe and has a beneficial effect on proteinuria dependent on its effect on platelets in renal disease.Keywords
This publication has 6 references indexed in Scilit:
- Membranoproliferative GlomerulonephritisNew England Journal of Medicine, 1984
- Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritisAmerican Journal Of Medicine, 1983
- EFFECTS OF VARIOUS ANTI-PLATELET DRUGS AND A DEFIBRINATING AGENT ON EXPERIMENTAL GLOMERULONEPHRITIS IN RATS1982
- BETA-THROMBOGLOBULIN AND PLATELET AGGREGATES IN GLOMERULONEPHRITIS1980
- Beta-thromboglobulin is elevated in renal failure without thrombosisThrombosis Research, 1979
- The release of a human platelet specific protein measured by a radioimmunoassayThrombosis Research, 1975